• Xavier B Pivot, Rubi K Li, Eva S Thomas, Hyun-Cheol Chung, Luis E Fein, Valorie F Chan, Jacek Jassem, Fernando Hurtado de Mendoza, Pralay Mukhopadyay, and Henri H Roché.
• Medical Oncology University Hospital, Service Oncologie, Boulevard Fleming, Besançon, Inserm U645, France. xavier.pivot@univ-fcomte.fr
• Eur. J. Cancer. 2009 Nov 1; 45 (17): 2940-6.

AbstractOestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.

46 keywords...

hide…